- call +1-201-465-4211
- email sales@mrinsights.biz
A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
Scope of the Report:
This report focuses on the Monoclonal antibodies (mAbs) Biosimilars in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
The worldwide market for Monoclonal antibodies (mAbs) Biosimilars is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Others
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Market Segment by Applications, can be divided into
Anti-Cancer
Anti-Inflammatory/Autoimmune
There are 15 Chapters to deeply display the global Monoclonal antibodies (mAbs) Biosimilars market.
Chapter 1, to describe Monoclonal antibodies (mAbs) Biosimilars Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Monoclonal antibodies (mAbs) Biosimilars, with sales, revenue, and price of Monoclonal antibodies (mAbs) Biosimilars, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Monoclonal antibodies (mAbs) Biosimilars, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Monoclonal antibodies (mAbs) Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Monoclonal antibodies (mAbs) Biosimilars sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Monoclonal antibodies (mAbs) Biosimilars Introduction
1.2 Market Analysis by Type
1.2.1 Erythropoietin (EPO)
1.2.2 Human Growth Hormone (HGH)
1.2.3 Granulocyte- Colony Stimulating Factor (G-CSF)
1.2.4 Monoclonal Antibody (mAb)
1.2.5 Insulin
1.2.6 Interferon (IFN)
1.2.7 Others
1.3 Market Analysis by Applications
1.3.1 Anti-Cancer
1.3.2 Anti-Inflammatory/Autoimmune
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Biocon
2.1.1 Business Overview
2.1.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Celltrion
2.2.1 Business Overview
2.2.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Dr. Reddy's Laboratories
2.3.1 Business Overview
2.3.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Hospira
2.4.1 Business Overview
2.4.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 3SBio
2.5.1 Business Overview
2.5.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Accord Healthcare
2.6.1 Business Overview
2.6.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 AET Biotech
2.7.1 Business Overview
2.7.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Allergan
2.8.1 Business Overview
2.8.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Amega Biotech
2.9.1 Business Overview
2.9.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Others
2.10.1 Business Overview
2.10.2 Monoclonal antibodies (mAbs) Biosimilars Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Others Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Monoclonal antibodies (mAbs) Biosimilars Manufacturer Market Share in 2017
3.3.2 Top 6 Monoclonal antibodies (mAbs) Biosimilars Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Monoclonal antibodies (mAbs) Biosimilars Market Analysis by Regions
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue and Market Share by Regions
4.1.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales and Market Share by Regions (2013-2018)
4.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Regions (2013-2018)
4.2 North America Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
4.3 Europe Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
4.5 South America Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
5 North America Monoclonal antibodies (mAbs) Biosimilars by Countries
5.1 North America Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue and Market Share by Countries
5.1.1 North America Monoclonal antibodies (mAbs) Biosimilars Sales and Market Share by Countries (2013-2018)
5.1.2 North America Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Countries (2013-2018)
5.2 United States Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
5.3 Canada Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
5.4 Mexico Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
6 Europe Monoclonal antibodies (mAbs) Biosimilars by Countries
6.1 Europe Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue and Market Share by Countries
6.1.1 Europe Monoclonal antibodies (mAbs) Biosimilars Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Countries (2013-2018)
6.2 Germany Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
6.3 UK Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
6.4 France Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
6.5 Russia Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
6.6 Italy Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
7 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars by Countries
7.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Countries (2013-2018)
7.2 China Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
7.3 Japan Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
7.4 Korea Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
7.5 India Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
8 South America Monoclonal antibodies (mAbs) Biosimilars by Countries
8.1 South America Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue and Market Share by Countries
8.1.1 South America Monoclonal antibodies (mAbs) Biosimilars Sales and Market Share by Countries (2013-2018)
8.1.2 South America Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
8.3 Argentina Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
8.4 Colombia Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
9 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars by Countries
9.1 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
9.3 UAE Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
9.4 Egypt Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
9.5 Nigeria Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
9.6 South Africa Monoclonal antibodies (mAbs) Biosimilars Sales and Growth Rate (2013-2018)
10 Global Monoclonal antibodies (mAbs) Biosimilars Market Segment by Type
10.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales and Market Share by Type (2013-2018)
10.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Type (2013-2018)
10.2 Erythropoietin (EPO) Sales Growth and Price
10.2.1 Global Erythropoietin (EPO) Sales Growth (2013-2018)
10.2.2 Global Erythropoietin (EPO) Price (2013-2018)
10.3 Human Growth Hormone (HGH) Sales Growth and Price
10.3.1 Global Human Growth Hormone (HGH) Sales Growth (2013-2018)
10.3.2 Global Human Growth Hormone (HGH) Price (2013-2018)
10.4 Granulocyte- Colony Stimulating Factor (G-CSF) Sales Growth and Price
10.4.1 Global Granulocyte- Colony Stimulating Factor (G-CSF) Sales Growth (2013-2018)
10.4.2 Global Granulocyte- Colony Stimulating Factor (G-CSF) Price (2013-2018)
10.5 Monoclonal Antibody (mAb) Sales Growth and Price
10.5.1 Global Monoclonal Antibody (mAb) Sales Growth (2013-2018)
10.5.2 Global Monoclonal Antibody (mAb) Price (2013-2018)
10.6 Insulin Sales Growth and Price
10.6.1 Global Insulin Sales Growth (2013-2018)
10.6.2 Global Insulin Price (2013-2018)
10.7 Interferon (IFN) Sales Growth and Price
10.7.1 Global Interferon (IFN) Sales Growth (2013-2018)
10.7.2 Global Interferon (IFN) Price (2013-2018)
10.8 Others Sales Growth and Price
10.8.1 Global Others Sales Growth (2013-2018)
10.8.2 Global Others Price (2013-2018)
11 Global Monoclonal antibodies (mAbs) Biosimilars Market Segment by Application
11.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Application (2013-2018)
11.2 Anti-Cancer Sales Growth (2013-2018)
11.3 Anti-Inflammatory/Autoimmune Sales Growth (2013-2018)
12 Monoclonal antibodies (mAbs) Biosimilars Market Forecast (2018-2023)
12.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales, Revenue and Growth Rate (2018-2023)
12.2 Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Regions (2018-2023)
12.2.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Forecast (2018-2023)
12.2.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Forecast (2018-2023)
12.2.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Forecast (2018-2023)
12.2.4 South America Monoclonal antibodies (mAbs) Biosimilars Market Forecast (2018-2023)
12.2.5 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Market Forecast (2018-2023)
12.3 Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Type (2018-2023)
12.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales Forecast by Type (2018-2023)
12.3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share Forecast by Type (2018-2023)
12.4 Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Application (2018-2023)
12.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales Forecast by Application (2018-2023)
12.4.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Monoclonal antibodies (mAbs) Biosimilars Picture
Table Product Specifications of Monoclonal antibodies (mAbs) Biosimilars
Figure Global Sales Market Share of Monoclo
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
